Johnson & Johnson reports new data from Phase 3 ICONIC-TOTAL study

Johnson & Johnson announced new data from the Phase 3 ICONIC-TOTAL study investigating icotrokinra, or JNJ-2113, the first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. The study evaluated adults and adolescents 12 years of age and older with body surface area as low as 1% and at least moderate plaque psoriasis, or PsO, affecting high-impact skin sites. Data presented at the 2025 Society for Investigative Dermatology, or SID, Annual Meeting show 57% of patients treated with once daily icotrokinra achieved the study’s primary endpoint with an Investigator’s Global Assessment, or IGA, score of 0/1 and a greater than or equal to2-grade improvement from baseline at Week 16 compared to 6% of patients receiving placebo. Icotrokinra demonstrated high rates of skin clearance in patients with scalp psoriasis as 66% achieved a scalp-specific Investigator’s Global Assessment, or ss-IGA, score of 0/1 compared to 11% receiving placebo (Pless than0.001) at Week 16. At the same time point, among patients with genital psoriasis, 77% treated with icotrokinra achieved a static Physician’s Global Assessment of Genitalia score of 0/1 compared to 21% receiving placebo. In the smaller subset of patients with hand/foot psoriasis, treatment with icotrokinra showed a numerically higher rate of skin clearance at Week 16 with 42% achieving a hand and/or foot Physician’s Global Assessment score of 0/1 compared to 26% receiving placebo. Icotrokinra demonstrated a favorable safety profile